WO2024013504A1 - Composition comprenant du cannabidiol destinée à être utilisée avec un nébuliseur - Google Patents
Composition comprenant du cannabidiol destinée à être utilisée avec un nébuliseur Download PDFInfo
- Publication number
- WO2024013504A1 WO2024013504A1 PCT/GB2023/051840 GB2023051840W WO2024013504A1 WO 2024013504 A1 WO2024013504 A1 WO 2024013504A1 GB 2023051840 W GB2023051840 W GB 2023051840W WO 2024013504 A1 WO2024013504 A1 WO 2024013504A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- essential oil
- composition
- nebuliser
- essential
- oil
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 112
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title claims abstract description 54
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title claims abstract description 54
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 229950011318 cannabidiol Drugs 0.000 title claims abstract description 54
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title claims abstract description 54
- 239000000341 volatile oil Substances 0.000 claims abstract description 231
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000011859 microparticle Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 235000011203 Origanum Nutrition 0.000 claims description 10
- 240000000783 Origanum majorana Species 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 229930003827 cannabinoid Natural products 0.000 claims description 6
- 239000003557 cannabinoid Substances 0.000 claims description 6
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 5
- 235000005979 Citrus limon Nutrition 0.000 claims description 5
- 244000131522 Citrus pyriformis Species 0.000 claims description 5
- 241001672694 Citrus reticulata Species 0.000 claims description 5
- 240000000560 Citrus x paradisi Species 0.000 claims description 5
- 244000301850 Cupressus sempervirens Species 0.000 claims description 5
- 235000017897 Cymbopogon citratus Nutrition 0.000 claims description 5
- 240000004784 Cymbopogon citratus Species 0.000 claims description 5
- 244000166124 Eucalyptus globulus Species 0.000 claims description 5
- 241000208152 Geranium Species 0.000 claims description 5
- 235000002598 Inula helenium Nutrition 0.000 claims description 5
- 244000116484 Inula helenium Species 0.000 claims description 5
- 244000165082 Lavanda vera Species 0.000 claims description 5
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 5
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 5
- 244000024873 Mentha crispa Species 0.000 claims description 5
- 235000014749 Mentha crispa Nutrition 0.000 claims description 5
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 5
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 5
- 235000010672 Monarda didyma Nutrition 0.000 claims description 5
- 244000179970 Monarda didyma Species 0.000 claims description 5
- 235000010676 Ocimum basilicum Nutrition 0.000 claims description 5
- 240000007926 Ocimum gratissimum Species 0.000 claims description 5
- 235000012550 Pimpinella anisum Nutrition 0.000 claims description 5
- 240000004760 Pimpinella anisum Species 0.000 claims description 5
- 240000005809 Prunus persica Species 0.000 claims description 5
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 5
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 5
- 240000002657 Thymus vulgaris Species 0.000 claims description 5
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 5
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 5
- 244000273928 Zingiber officinale Species 0.000 claims description 5
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 5
- 235000008397 ginger Nutrition 0.000 claims description 5
- 239000001102 lavandula vera Substances 0.000 claims description 5
- 235000018219 lavender Nutrition 0.000 claims description 5
- 239000004571 lime Substances 0.000 claims description 5
- 235000002020 sage Nutrition 0.000 claims description 5
- 239000001585 thymus vulgaris Substances 0.000 claims description 5
- 241000271309 Aquilaria crassna Species 0.000 claims description 4
- 235000003717 Boswellia sacra Nutrition 0.000 claims description 4
- 240000007551 Boswellia serrata Species 0.000 claims description 4
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 4
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 4
- 240000003538 Chamaemelum nobile Species 0.000 claims description 4
- 239000004863 Frankincense Substances 0.000 claims description 4
- 235000010254 Jasminum officinale Nutrition 0.000 claims description 4
- 240000005385 Jasminum sambac Species 0.000 claims description 4
- 241000721662 Juniperus Species 0.000 claims description 4
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 4
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 4
- 240000002853 Nelumbo nucifera Species 0.000 claims description 4
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 4
- 244000215777 Plumeria rubra Species 0.000 claims description 4
- 235000013087 Plumeria rubra Nutrition 0.000 claims description 4
- 244000290333 Vanilla fragrans Species 0.000 claims description 4
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 4
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 4
- 240000002505 Pogostemon cablin Species 0.000 claims description 3
- 235000011751 Pogostemon cablin Nutrition 0.000 claims description 3
- 235000016067 Polianthes tuberosa Nutrition 0.000 claims description 3
- 244000014047 Polianthes tuberosa Species 0.000 claims description 3
- 241000220317 Rosa Species 0.000 claims description 3
- 235000008632 Santalum album Nutrition 0.000 claims description 3
- 240000000513 Santalum album Species 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 13
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 13
- 229960004242 dronabinol Drugs 0.000 description 13
- ZLYNXDIDWUWASO-UHFFFAOYSA-N 6,6,9-trimethyl-3-pentyl-8,10-dihydro-7h-benzo[c]chromene-1,9,10-triol Chemical compound CC1(C)OC2=CC(CCCCC)=CC(O)=C2C2=C1CCC(C)(O)C2O ZLYNXDIDWUWASO-UHFFFAOYSA-N 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 240000004308 marijuana Species 0.000 description 8
- 239000006199 nebulizer Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RBEAVAMWZAJWOI-MTOHEIAKSA-N (5as,6s,9r,9ar)-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-1,6-diol Chemical compound C1=2C(O)=CC(CCCCC)=CC=2O[C@H]2[C@@H]1[C@H](C(C)=C)CC[C@]2(C)O RBEAVAMWZAJWOI-MTOHEIAKSA-N 0.000 description 4
- TWKHUZXSTKISQC-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C TWKHUZXSTKISQC-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 3
- 229940065144 cannabinoids Drugs 0.000 description 3
- 239000002621 endocannabinoid Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000011624 Agave sisalana Nutrition 0.000 description 2
- 244000198134 Agave sisalana Species 0.000 description 2
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- IGHTZQUIFGUJTG-QSMXQIJUSA-N O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 Chemical compound O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 IGHTZQUIFGUJTG-QSMXQIJUSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000002199 base oil Substances 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 2
- 235000005607 chanvre indien Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000007539 photo-oxidation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000011552 falling film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000000196 viscometry Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Definitions
- This invention generally relates to a composition comprising cannabidiol, and particularly, although not exclusively, to a composition comprising cannabidiol for use with a nebuliser, and a method of nebulising the composition.
- CBD cannabidiol
- THC tetrahydrocannabinol
- Medical cannabis CBD and THC
- CBD is a non-psychotropic compound, and many studies have shown huge potential therapeutic benefits that CBD can produce, when applied topically or consumed through edible form or inhalation.
- CBD interacts with the endocannabinoid system in a subject’s body.
- the endocannabinoid system is a network of neurotransmitters which the body’s cells use to communicate with each other, and it handles vital functions such as metabolism, appetite, sleep patterns, nausea and vomiting, pain sensation and perception, blood pressure, memory, inflammation, cravings and emotional wellbeing.
- CBD extracts are believed to provide a number of positive benefits to the endocannabinoid system, and the recreational use of CBD products is gaining popularity nowadays.
- composition for use with a nebuliser comprising cannabidiol and at least one essential oil.
- composition further comprising at least one other cannabinoid.
- the at least one essential oil is selected from a group consisting of Neroli Essential Oil, Sandalwood Essential Oil, Elecampane Essential Oil, Rose Essential Oil, Agarwood Essential Oil, Frangipani Absolute Essential Oil, Mint Essential Oil, Spearmint Essential Oil, Vanilla Essential Oil, Geranium Essential Oil, Juniper Essential Oil, Patchouli Essential Oil, Lavender Essential Oil, Clary Sage Essential Oil, Chamomile Essential Oil, Grapefruit Essential Oil, Jasmine Essential Oil, Orange Flower Essential Oil, Tuberose Essential Oil, Cashmere Woods Essential Oil, Ylang Yang Essential Oil, Eucalyptus Essential Oil, Frankincense Essential Oil, Marjoram Essential Oil, Lime Essential Oil, Lemon Essential Oil, Basil Essential Oil, Mandarin Essential Oil, Peach Essential Oil, Plum Essential Oil, Sicilian Thyme Essential Oil, Bergamot Essential Oil, Aniseed Essential Oil, Bay Essential Oil, Birch Sweet Essential Oil, Cypress Essential Oil, Ginger Essential Oil, Lemongrass Essential Oil, Lotus Pink Essential Oil, Lotus White Essential Oil, Marjor
- the composition further comprises an antioxidant.
- the antioxidant is vitamin E.
- the concentration of cannabidiol is about 1-30% w/v; preferably about 5-20% w/v; more preferably about 10% w/v.
- the concentration of the at least one essential oil is about 70-99% w/v; more preferably about 80-95% w/v; most preferably about 90% w/v.
- the composition has a viscosity of less than about 2,000 mPa.s at 20°C; preferably less than about 1,000 mPa.s at 20°C; more preferably less than about 500 mPa.s at 20°C; most preferably less than about 200 mPa.s at 20°C.
- a container comprising the composition.
- the container is a black, brown or amber glass bottle.
- the bottle has a volume of about 10-50 mL.
- the bottle has a volume of about 30 mL.
- kits comprising the composition and a nebuliser.
- the kit further comprises a container for containing the composition.
- a method of nebulising a composition comprising the steps of: providing the composition to a nebuliser, atomising the composition into microparticles by the nebuliser; and releasing the microparticles to the surroundings.
- the step of atomising the composition into microparticles is performed by passing a stream of gas through the composition.
- the present invention provides a composition for use with a nebuliser, comprising cannabidiol (CBD) and at least one essential oil.
- CBD cannabidiol
- the cannabidiol is extracted from industrial cannabis plants, or hemp plants.
- the seeds can be obtained from, for example, cannabis sativa and cannabis indica plants.
- varieties of hemp plants have a tetrahydrocannabinol (THC) level of less than 0.3%, but more preferably less than 0.2%.
- THC tetrahydrocannabinol
- Cannabidiol can be extracted using existing methods, for example but not limited to supercritical carbon dioxide extraction, and alcohol extraction.
- Supercritical carbon dioxide extraction method uses a closed-loop extractor. The hemp is placed in a pressure chamber which is then loaded with supercritical carbon dioxide. The carbon dioxide acts as a solvent, resulting in a fluid consisting of carbon dioxide and CBD, which is then passed through a final chamber to separate the carbon dioxide and CBD.
- Alcohol extraction method uses liquid solvents such as ethanol to extract CBD from the plant material. The hemp is soaked in ethanol which is chilled to about -40°C in an extraction chamber, and the resulting solvent is evaporated using rotary evaporation or falling film evaporation to obtain the desired CBD extracts.
- the composition further comprises at least one other cannabinoid, for example but not limited to tetrahydrocannabinol (THC), cannabigerols (CBG), cannabichromenes (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabielsoin (CBE), cannabitriol (CBT) and cannabidiolic acid (CBDA).
- THC tetrahydrocannabinol
- CBD cannabigerols
- CBC cannabichromenes
- CBD cannabinol
- CBN cannabinodiol
- CBDL cannabicyclol
- CBE cannabielsoin
- CBT cannabitriol
- CBDA cannabidiolic acid
- the composition only contains a negligible amount of cannabinoids other than cannabidiol (CBD).
- the composition comprises less than about 0.1% THC, or less than about 0.05% THC, or less than about 0.01% THC.
- the composition comprises cannabigerols (CBG), cannabichromenes (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabielsoin (CBE), cannabitriol (CBT), cannabidiolic acid (CBDA) or combinations thereof, but without any amount of tetrahydrocannabinol (THC).
- CBD cannabigerols
- CBC cannabichromenes
- CBN cannabinol
- CBDL cannabinodiol
- CBL cannabicyclol
- CBE cannabielsoin
- CBT cannabitriol
- CBDA cannabidiolic acid
- the essential oils in the composition are oils derived from plants, containing essence of the plant’s fragrance. Suitable existing methods can be used to extract essential oils from plants, such as distillation, solvent extraction, and cold pressing.
- the composition comprises only one essential oil.
- the composition comprises two or more essential oils. The kind of essential oil, or combination of essential oils is selected based on different factors such as intended therapeutic effects, intended health benefits, scents, thickness and strain of cannabis.
- the composition contains only at least one essential oil and CBD. In other words, in those embodiments, the composition consists essentially of at least one essential oil and CBD.
- the one or more essential oils may be selected from the group consisting of Neroli Essential Oil, Sandalwood Essential Oil, Elecampane Essential Oil, Rose Essential Oil, Agarwood Essential Oil, Frangipani Absolute Essential Oil, Mint Essential Oil, Spearmint Essential Oil, Vanilla Essential Oil, Geranium Essential Oil, Juniper Essential Oil, Patchouli Essential Oil, Lavender Essential Oil, Clary Sage Essential Oil, Chamomile Essential Oil, Grapefruit Essential Oil, Jasmine Essential Oil, Orange Flower Essential Oil, Tuberose Essential Oil, Cashmere Woods Essential Oil, Ylang Yang Essential Oil, Eucalyptus Essential Oil, Frankincense Essential Oil, Marjoram Essential Oil, Lime Essential Oil, Lemon Essential Oil, Basil Essential Oil, Mandarin Essential Oil, Peach Essential Oil, Plum Essential Oil, Sicilian Thyme Essential Oil, Bergamot Essential Oil, Aniseed Essential Oil, Bay Essential Oil, Birch Sweet Essential Oil, Cypress Essential Oil, Ginger Essential Oil, Lemongrass Essential Oil, Lotus Pink Essential Oil, Lotus White Essential Oil, Marjoram
- the one or more essential oils is selected from a group consisting of medium to low viscosity Essential Oils: Neroli Essential Oil, Elecampane Essential Oil, Agarwood Essential Oil, Frangipani Absolute Essential Oil, Mint Essential Oil, Spearmint Essential Oil, Vanilla Essential Oil, Geranium Essential Oil, Juniper Essential Oil, Lavender Essential Oil, Chamomile Essential Oil, Grapefruit Essential Oil, Jasmine Essential Oil, Orange Flower Essential Oil, Cashmere Woods Essential Oil, Ylang Yang Essential Oil, Eucalyptus Essential Oil, Frankincense Essential Oil, Marjoram Essential Oil, Lime Essential Oil, Lemon Essential Oil, Basil Essential Oil, Mandarin Essential Oil, Peach Essential Oil, Plum Essential Oil, Sicilian Thyme Essential Oil, Bergamot Essential Oil, Aniseed Essential Oil, Bay Essential Oil, Birch Sweet Essential Oil, Cypress Essential Oil, Ginger Essential Oil, Lemongrass Essential Oil, Lotus Pink Essential Oil, Lotus White Essential Oil, Marjoram Essential Oil, Rosemary Essential Oil, Sage Dalmatian Essential Oil
- the one or more essential oils is selected from a group consisting of relatively low viscosity Essential Oils: Neroli Essential Oil, Elecampane Essential Oil, Mint Essential Oil, Spearmint Essential Oil, Geranium Essential Oil, Lavender Essential Oil, Grapefruit Essential Oil, Orange Flower Essential Oil, Cashmere Woods Essential Oil, Eucalyptus Essential Oil, Marjoram Essential Oil, Lime Essential Oil, Lemon Essential Oil, Basil Essential Oil, Mandarin Essential Oil, Peach Essential Oil, Plum Essential Oil, Sicilian Thyme Essential Oil, Bergamot Essential Oil, Aniseed Essential Oil, Bay Essential Oil, Birch Sweet Essential Oil, Cypress Essential Oil, Ginger Essential Oil, Lemongrass Essential Oil, Marjoram Essential Oil, Rosemary Essential Oil, Sage Dalmatian Essential Oil, Tea Tree Essential Oil and combinations thereof.
- the composition further comprises solvents such as alcohols.
- solvents such as alcohols.
- ethanol and/or isopropyl alcohol may be added to the composition to make the composition less thick or viscous.
- the composition may contain a carrier oil in addition to the at least one essential oil. This is preferable in the situation where the composition would otherwise have a viscosity which would impede or prevent the effective operation of the nebulizer.
- a carrier oil can reduce the overall viscosity of the composition to a desired level.
- the composition further comprises an antioxidant.
- vitamin E may be added to the composition as an antioxidant.
- the addition of an antioxidant may help to preserve the desired aroma and characteristics of the composition.
- the composition may be obtained by combining the components by any suitable methods.
- cannabidiol (CBD) and one or more essential oils can be combined by mixing using a high shear mixer.
- the temperature is kept below 60°C during the process, and the components are kept out of light to prevent damages due to photooxidation.
- the composition goes through a filtering process before being placed into containers to ensure no particulates remains to prevent the composition from clogging a nebuliser during use.
- the volume concentration of cannabidiol (CBD) in the composition depends on different factors, such as the required strength of the composition, the desired viscosity of the composition, the type of essential oil(s) used, and the presence of alcohol and/or antioxidant, etc.
- the volume concentration of cannabidiol (CBD) in the composition is about 1 to 30% w/v.
- the volume concentration of cannabidiol (CBD) in the composition is about 5 to 20% w/v. More preferably, the volume concentration of cannabidiol (CBD) in the composition is about 10% w/v.
- the volume concentration of essential oil(s) in the composition depends on factors such as the desired strength of scent, type of essential oil(s) used, the desired viscosity of the composition, etc. In some embodiments, the volume concentration of essential oil(s) in the composition is about 70 to 99% w/v. Preferably, the volume concentration of cannabidiol (CBD) in the composition is about 80 to 95% w/v. More preferably, the volume concentration of cannabidiol (CBD) in the composition is about 90% w/v. [0039]
- the composition in the present invention is suitable for use with a nebuliser, and therefore a low level of viscosity is desired so as to diffuse and nebulise the composition well.
- Viscosity refers to the resistance of the composition to deformation under shear stress and/or tensile stress.
- the composition has a viscosity of less than about 2,000 mPa.s at 20°C.
- the composition has a viscosity of less than about 1,000 mPa.s at 20°C.
- the composition has a viscosity of less than about 500 mPa.s at 20°C.
- the composition has a viscosity of less than about 200 mPa.s at 20°C. Viscosity can be readily determined by referring to known values or experimentally using well known methods such as rotational viscometry.
- compositions of the invention generally contain a low or negligible amount of water, such as less than 1% w/v, preferably less than 0.5% w/v.
- the compositions preferably contain one non-aqueous phase without the presence of a separate aqueous phase.
- Tables 1 and 2 below illustrate two examples of compositions of the invention.
- the container comprising the composition described herein.
- the container is a black, brown or amber glass bottle, or similar coloured plastic container, which acts an effective barrier between the composition and light.
- Such a container can protect the composition against damage from light, or photooxidation, which can adversely affect the quality and aroma of the composition.
- the container has a volume of about 10 to 50 mL.
- the container has a volume of about 30 mL.
- kits comprising the composition described herein, and a nebuliser.
- the kit also comprises the container described above.
- the nebuliser uses a pressurised gas (typically air) stream to atomise and distribute the composition to the surrounding air without the use of heat or water.
- a pressurised gas typically air
- the composition is placed in the nebulizer, for example in a reservoir.
- a flow of air is then created by the nebulizer to act on the composition to create a dispersion of very small particles of the composition.
- the flow of gas can pass through the composition or act on the surface of the composition.
- the nebulizer uses the Bernoulli principle to help nebulise the composition.
- the composition may be provided in a reservoir with a small outlet near the outlet for the flow of air.
- An air current is then forced through the narrow outlet, creating a low pressure area near the outlet of the composition.
- This low pressure effect causes the composition to rise upwards in outlet of the reservoir, until the flow of air impinges on the surface of the composition, causing it to atomise into microparticles in air flow stream.
- the atomised microparticles are released out of the nebulizer and into the surroundings.
- nebuliser to atomise and release the composition in the form of microparticles which is then to be inhaled by the users is advantageous in that it increases the bioavailability of the composition, and hence the composition is more readily absorbed by the body. Furthermore, nebulising the composition does not require heat or water. This allows the cannabidiol (CBD) and the essential oil(s) in the composition to be diffused more effectively. Other methods of diffusing the composition using heat or water would damage and dilute the composition, and thus destroying the original therapeutic benefits brought about by the composition. In particular, CBD can undergo thermal degradation, lowering the amount of CBD present and also creating degradation products, which may include unwanted cannabinoids other than CBD.
- CBD can undergo thermal degradation, lowering the amount of CBD present and also creating degradation products, which may include unwanted cannabinoids other than CBD.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Fats And Perfumes (AREA)
Abstract
L'invention concerne une composition destinée à être utilisée avec un nébuliseur, comprenant du cannabidiol et au moins une huile essentielle. L'invention concerne également un contenant et un kit comprenant ladite composition. Elle concerne également un procédé de nébulisation de ladite composition, comprenant les étapes consistant à : fournir ladite composition à un nébuliseur ; atomiser la composition en microparticules par le nébuliseur ; et libérer les microparticules dans l'environnement.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2210304.8 | 2022-07-13 | ||
| GBGB2210304.8A GB202210304D0 (en) | 2022-07-13 | 2022-07-13 | Composition comprising cannabidiol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024013504A1 true WO2024013504A1 (fr) | 2024-01-18 |
Family
ID=84540049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2023/051840 WO2024013504A1 (fr) | 2022-07-13 | 2023-07-13 | Composition comprenant du cannabidiol destinée à être utilisée avec un nébuliseur |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202210304D0 (fr) |
| WO (1) | WO2024013504A1 (fr) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170259016A1 (en) * | 2015-09-16 | 2017-09-14 | Jynyvy Covarrubias | Nebulizers and associated medication |
| US20180344661A1 (en) * | 2015-11-24 | 2018-12-06 | Constance Therapeutics, Inc. | Cannabis oil compositions and methods for preparation thereof |
| WO2019034936A2 (fr) * | 2017-08-13 | 2019-02-21 | Buzzelet Development And Technologies Ltd | Composition de cannabinoïde enrichie en terpène et procédé de traitement |
| US20190275270A1 (en) * | 2018-03-07 | 2019-09-12 | Richard Postrel | System and method for arresting debilitating migraine events |
| US20210113490A1 (en) * | 2019-10-21 | 2021-04-22 | Avicanna Inc. | Topical cannabinoid compositions for clear skin |
| US20210322366A1 (en) * | 2018-12-27 | 2021-10-21 | Buzzelet Development And Technologies Ltd. | Herbal preparation-enriched cannabinoid composition and methods of treatment |
-
2022
- 2022-07-13 GB GBGB2210304.8A patent/GB202210304D0/en not_active Ceased
-
2023
- 2023-07-13 WO PCT/GB2023/051840 patent/WO2024013504A1/fr unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170259016A1 (en) * | 2015-09-16 | 2017-09-14 | Jynyvy Covarrubias | Nebulizers and associated medication |
| US20180344661A1 (en) * | 2015-11-24 | 2018-12-06 | Constance Therapeutics, Inc. | Cannabis oil compositions and methods for preparation thereof |
| WO2019034936A2 (fr) * | 2017-08-13 | 2019-02-21 | Buzzelet Development And Technologies Ltd | Composition de cannabinoïde enrichie en terpène et procédé de traitement |
| US20190275270A1 (en) * | 2018-03-07 | 2019-09-12 | Richard Postrel | System and method for arresting debilitating migraine events |
| US20210322366A1 (en) * | 2018-12-27 | 2021-10-21 | Buzzelet Development And Technologies Ltd. | Herbal preparation-enriched cannabinoid composition and methods of treatment |
| US20210113490A1 (en) * | 2019-10-21 | 2021-04-22 | Avicanna Inc. | Topical cannabinoid compositions for clear skin |
Also Published As
| Publication number | Publication date |
|---|---|
| GB202210304D0 (en) | 2022-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9849108B2 (en) | Composition with pharmacological effect for vaporizing and method | |
| Ali et al. | Effect of nanoencapsulation on volatile constituents, and antioxidant and anticancer activities of Algerian Origanum glandulosum Desf. essential oil | |
| Aziz et al. | Enrichment of Eucalyptus oil nanoemulsion by micellar nanotechnology: Transdermal analgesic activity using hot plate test in rats’ assay | |
| US20180221333A1 (en) | Optimized cannabis-based aphrodisiac and mood enhancer | |
| US10172897B2 (en) | Enhanced smokable therapeutic cannabis product and method for making same | |
| US20180352848A1 (en) | Smokable cannabis-based product with reduced psychoactive effects | |
| CA3106840A1 (fr) | Substances hydrophobes en nanoemulsion | |
| US20190175523A1 (en) | Cannabis-based therapeutic product for treatment of chronic pain | |
| CN108697665A (zh) | 局部镇痛性疼痛缓解制剂、其制备和使用方法 | |
| US20180344786A1 (en) | System and method enhanced cannabiniod effect delivery | |
| US20190269865A1 (en) | Multi-use cartridge for ingestion of cannabis-based products | |
| US20160309774A1 (en) | Terpene carrier | |
| CN104274634A (zh) | 一种提神醒脑及消肿止痒的复方植物精油及其制备方法 | |
| US10736869B2 (en) | Compositions and methods related to cannabinoids, terpenoids and essential oils | |
| US20170367386A1 (en) | Terpene flavoring compositions | |
| US10981856B1 (en) | Infusing raw cannabinoids into food oil | |
| Sangolkar et al. | Ultrasound assisted encapsulation of peppermint flavor in gum Arabic: Study of process parameters | |
| US10258601B1 (en) | Vaporizable cannabinoid compositions | |
| US20190321306A1 (en) | Cannabis-based therapeutic product for treatment of chronic pain | |
| Santana de Oliveira et al. | Bioactive compounds present in essential oils: Advances and pharmacological applications | |
| WO2024013504A1 (fr) | Composition comprenant du cannabidiol destinée à être utilisée avec un nébuliseur | |
| Rao et al. | Extraction of essential oil and its applications | |
| Karaca et al. | Enhanced bioactivity of rosemary, sage, lavender, and chamomile essential oils by fractionation, combination, and emulsification | |
| Rashed et al. | Two-phase extraction processes, physicochemical characteristics, and autoxidation inhibition of the essential oil nanoemulsion of citrus reticulata blanco (tangerine) leaves | |
| Lai et al. | Preparation and evaluation of microcapsules containing Rimulus Cinnamon and Angelica Sinenis essential oils |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23754347 Country of ref document: EP Kind code of ref document: A1 |